Depression: all studies (page 34) - The Consciousness Library

Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.

Current Topics in Medicinal Chemistry May 21, 2026 Guizhen Lyu, Dongbing Li

Depression is a leading cause of global disability, affecting over 300 million individuals and imposing substantial personal, clinical, and societal burdens. This comprehensive review synthesizes recent advances in understanding depression across biological, cognitive, and psychosocial domains, emphasizing innovations in diagnosis, pathophysiology, and treatment. We explore emerging...

DOI: 10.2174/0115680266437457251129112908 Full text Major depressive disorder Psychedelic therapy Treatment-resistant depression Neuroinflammation +1

Effect of ketamine intervention on hemodynamic responses in patients with treatment-resistant depression.

Scientific Reports May 20, 2026 Guan-Jie She, Wei-Chi Li, Chun-Hsiang Chou et al.

Emerging evidence shows that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, can produce rapid anti-suicidal effects in treatment-resistant depression, yet its underlying neuropharmacological mechanisms remain elusive. The present study aimed at investigating the therapeutic effect of ketamine infusion on suicidal ideation by examining hemodynamic response changes in resting-state...

DOI: 10.1038/s41598-026-51314-3 Full text

Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.

Pharmacological Reports May 20, 2026 Aleksander Kwaśny, Alina Wilkowska, Michał Pastuszak et al.

Background: Treatment-resistant depression (TRD) poses a significant therapeutic challenge, with remission often unattainable. Recognition and detection of treatment-emergent adverse events (TEAEs) are essential, as these events may significantly influence the quality of treatment response. This knowledge aids in personalizing care and selecting the best treatment strategy. Methods: In a...

DOI: 10.1007/s43440-026-00867-1 Ketamine Major depressive disorder Humans Antidepressive agents +8

Interplay between the HPA axis and inflammation as mechanisms therapeutic targets of Cannabis sativa in depression

Frontiers in Pharmacology May 19, 2026 Fernanda Pilatti, Marieli Philippsen, A. G. Bertollo et al.

Major Depressive Disorder (MDD) is a highly prevalent and disabling psychiatric disorder, representing a major global health burden across all age groups. Increasing evidence indicates that its pathophysiology involves a complex interplay between chronic stress, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, immune activation, and neuroinflammation. Persistent HPA axis...

DOI: 10.3389/fphar.2026.1801474 Full text

Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study".

Therapeutic Advances in Psychopharmacology May 19, 2026 correction

[This corrects the article DOI: 10.1177/20451253261437597.].

DOI: 10.1177/20451253261452482 Full text

The multilevel exploration test, a novel paradigm to measure exploratory behavior in depression animal models and the involvement of the PL-ZI circuit.

Acta pharmacologica Sinica May 19, 2026 Jun-Nan Xu, Jing-Ting Li, Ru-Xia Xu et al.

Diminished drive is one of the core symptoms of major depressive disorder (MDD) diagnosis, yet its underlying neural mechanisms remain elusive, primarily due to a lack of appropriate animal models. We developed a novel Multilevel Exploration Test (MET) apparatus to evaluate exploratory behavior, which is captured as a dynamic, stage-dependent process involving "search", "attend/investigate",...

DOI: 10.1038/s41401-026-01812-x Full text Anxiety Depression Ethology Motivation +1

The Effect of Mindfulness on Depression and Anxiety in Adults

Lecture Notes in Education Psychology and Public Media May 18, 2026 Fanyue Kong

Mindfulness meditation is increasingly recognized as an effective psychological intervention for emotional regulation. Millions of people worldwide suffer from depression and anxiety, which are the most common mental health conditions amd present significant public health issues. This study examines the effects of short-term mindfulness meditation on depression and anxiety in adults. A...

DOI: 10.54254/2753-7048/2026.ld33546

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

Journal of Affective Disorders May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation

Background: Off-label use of intravenous ketamine (IVK) for depression is a widespread practice with limited regulation in the United States. There is an urgent need for current, evidence-informed treatment guidelines to facilitate patient safety, clinical decision-making, and care quality in real-world contexts. Methods: The American Society of Ketamine Physicians, Psychotherapists and...

DOI: 10.1016/j.jad.2026.121970 Depressive disorder Depression Racemic ketamine Humans +10

Short-term effects of oral ketamine for the treatment of depression: A systematic review and meta-analysis of randomized controlled trials.

Asian Journal of Psychiatry May 16, 2026 Sonia Shenoy, Vijetha Shenoy Belle, Ravindra Neelakanthappa Munoli et al. 1 citation

Background: Oral ketamine is a novel treatment for management of depression. However, evidence related to its effectiveness and safety is unavailable. This systematic review aimed to assess the short-term efficacy and safety of oral ketamine compared to placebo or other modes of ketamine in randomized controlled trials (RCT) in unipolar depression, bipolar depression, and treatment-resistant...

DOI: 10.1016/j.ajp.2026.105014 Depression Humans Antidepressive agents Administration, oral +4

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression

JAMA Network Open May 15, 2026 Hampus Yngwe, Pontus Plavén-sigray, Carl Johan Ekman et al. 1 citation

Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population. Objective: To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This double-blind,...

DOI: 10.1001/jamanetworkopen.2026.12589

Research